Business Context and Reporting Period
This Form 6-K, filed on June 6, 2018, incorporates a presentation by Sol-Gel Technologies Ltd. (NASDAQ: SLGL) delivered at the Jefferies 2018 Global Healthcare Conference. The company is a clinical-stage biopharmaceutical firm based in Israel, focused on developing branded and generic topical dermatology drugs using a proprietary microencapsulation delivery system.
Key Financial Metrics
The filing provides limited financial data, primarily reflecting the company's capital position following its initial public offering (IPO) in February 2018.
- Cash Position: As of March 31, 2018, the company held $83.8 million in cash, cash equivalents, and deposits.
- Capital Raised: Gross proceeds of $86.3 million were raised in the IPO of 7,187,500 ordinary shares on February 5, 2018.
- Share Count: 18,949,968 shares were outstanding as of March 31, 2018.
- Revenue and Profit: The filing text does not provide specific revenue, profit, or cash flow figures for the reporting period. The company operates on a cost-sharing model for generic collaborations with 50/50 gross profit sharing.
- Liquidity: Management states the cash runway is expected to be sufficient to fund Phase III clinical programs for TWIN and EpsolayR, as well as a bioequivalence study.
Material Changes and Pipeline Status
The filing highlights significant progress in both branded and generic pipelines compared to prior periods:
- Generic Pipeline: Received tentative FDA approval for its first generic drug product, ivermectin cream 1% (Paragraph IV ANDA), as of January 29, 2018. This product is developed in collaboration with Perrigo.
- Branded Pipeline (Acne): Reported positive Phase II co-primary efficacy results for TWIN (benzoyl peroxide and tretinoin combination) and SIRS-T (encapsulated tretinoin) for acne vulgaris.
- Branded Pipeline (Rosacea): Reported positive Phase II co-primary efficacy results for EpsolayR (encapsulated benzoyl peroxide) for subtype II rosacea.
- Regulatory Milestones: Held End-of-Phase II meetings with the FDA for both EpsolayR and TWIN.
Guidance, Outlook, and Risks
Outlook and Milestones:
- EpsolayR: Phase III pivotal trials are planned to initiate in H1 2018 with readouts expected in 2019. Each trial plans to enroll 350 subjects.
- TWIN: Phase III pivotal trials are planned to initiate in H2 2018 with readouts expected in H2 2019.
- Generic Pipeline: Plans to initiate a bioequivalence study for another generic candidate in H2 2018.
- Commercialization: Plans to hire a U.S. commercialization leader for the launches of TWIN and EpsolayR.
Risks and Contingencies:
- Forward-Looking Statements: The document contains extensive cautionary notes regarding risks, uncertainties, and assumptions that could cause actual results to differ materially from projections.
- Regulatory Approval: Product candidates are investigational and have not been approved for marketing by the FDA or other authorities. No representations are made regarding safety or effectiveness.
- Comparative Data: The company explicitly states it did not conduct head-to-head comparison trials against competitors (e.g., Epiduo Forte, Soolantra); presented comparative data is for illustrative purposes only.
Investor Verification Checklist
- Verify the status of the tentative FDA approval for the ivermectin cream 1% ANDA and the timeline for final approval.
- Confirm the initiation dates and enrollment progress for the EpsolayR Phase III trials planned for H1 2018.
- Review the specific terms of the collaboration agreements with Perrigo and Douglas Pharmaceuticals regarding cost-sharing and profit splits.
- Monitor the hiring status of the U.S. commercialization leader to assess readiness for potential product launches.
- Validate the cash burn rate against the stated runway to ensure sufficiency for funding the planned Phase III programs through 2019.